Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Sangamo Therapeutics

Main focus: Gene editing using zing-finger nucleases for novel gene-ediing and cell therapies.

Company stage: Clinical

Diseases: Solid graft transplantations, beta-thalassemia, sickle cell disease, inflammatory bowel disease, multiple sclerosis, solid tumours, haematological cancers

Genome editing technology: Zinc finger nucleases (ZNFs)

Funding stage: Public (NASDAQ:SGMO)

Location: South San Francisco, CA, USA

Website: https://www.sangamo.com/

Pipeline: https://www.sangamo.com/pipeline

Partners: Sanofi, Takeda Pharma, Novartis, Pfizer, Kite Pharma, Biogen

Sangamo Therapeutics is the only company solely focused on the development of zinc finger nucleases (ZFNs) as a tool for genetic engineering. The company applies the tool for both ex vivo and in vivo-based gene-editing therapies, as well as a tool for genome regulation. The company is currently sponsoring clinical trials for sickle cell disease and beta-thalassemia, where ZFNs are applied for gene editing. The company holds multiple substantial collaborations with companies such Pfizer, Biogen, Novartis, Takeda, Sanofi and Kite Pharma.

Tags

HashtagSangamo Therapeutics Inc.

Company: Sangamo Therapeutics
close
Search CRISPR Medicine